AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Therion Biologics and Ludwig Institute Initiate Study of Cancer Vaccine.(Brief Article)
2002 JAN 23 - (NewsRx.com & NewsRx.net) -- The Ludwig Institute for Cancer Research has initiated the first European Phase I trial for Therion Biologics' two-component vaccine targeting the tumor antigen NY-ESO-1.
In this study, the Ludwig Institute will evaluate the safety and potential activity of Therion's pox virus-based vaccine for enhancing the body's own immune response against cancer. This initial clinical study will include patients with a wide variety of ESO-expressing tumors, including breast and bladder cancer, melanoma and sarcoma.
"The Ludwig Institute's efforts are dedicated to turning leading-edge science into novel treatments for a variety of cancers," said Lloyd J. Old, chief executive officer at the Ludwig Institute. "As the first product from our joint research efforts with Therion enters the clinic, we recognize and look forward to other milestones in this collaboration."
The Phase I dose-ranging trial will assess the safety and immunologic profile of recombinant vaccinia-NY-ESO-1 (rV-NY-ESO-1) and recombinant fowlpox-NY-ESO-1 (rF-NY-ESO-1) in approximately 60 patients with NY-ESO-1 expressing tumors and undetectable NY-ESO-1 specific serum antibodies. The study is designed to evaluate the utility of the "prime-boost" approach to cancer therapeutics, which works by priming the immune system with one species of poxvirus and boosting with another to increase immune response over time. In addition, researchers ...
- Therion Biologics and the Ludwig Institute Initiate Clinical Study of Cancer...
- Press release article from: PR Newswire January 2, 2002 700+ words
...antigen NY-ESO-1. In this study, the Ludwig Institute will evaluate...variety of ESO-expressing...patients. "The Ludwig Institute's efforts...tumors. The Ludwig Institute expects to...2003. NY-ESO-1 NY-ESO...
- Therion Obtains Rights to Novel Gene from Ludwig Institute for Cancer Vaccines
- Press release article from: PR Newswire September 16, 1998 700+ words
...acquired from the Ludwig Institute for Cancer...rights to NY-ESO-1, a novel...Director of the Ludwig Institute for Cancer Research. "ESO-1 is recognized...clinical trials of ESO-1 will be...researchers at the Ludwig Institute, and are expected...
- Therion Biologics and Ludwig Institute Initiate Study of Cancer Vaccine.(Brief...
- Newspaper article from: Cancer Weekly January 22, 2002 700+ words
...net) -- The Ludwig Institute for Cancer Research...tumor antigen NY-ESO-1. In this study, the Ludwig Institute will evaluate the...wide variety of ESO-expressing tumors...sarcoma. "The Ludwig Institute's efforts are...
- Dendreon and the Ludwig Institute for Cancer Research Announce Licensing...
- Press release article from: Business Wire August 12, 1998 700+ words
...for the use of the Ludwig Institute's NY-ESO-1 antigen in Dendreon...institution as the Ludwig Institute. The NY-ESO-1 antigen will extend...studies with NY-ESO-1 during 1999. The Ludwig Institute for Cancer Research...
- Ludwig Institute for Cancer Research and PowderMed Initiate A Phase I Clinical...
- Press release article from: PR Newswire September 17, 2004 700+ words
...with its partner, the Ludwig Institute for Cancer Research...encoding for the NY-ESO-1 tumour specific...vaccines based upon NY-ESO-1 potentially useful...the ability of NY-ESO-1 DNA formulated on...cancer (partnered with Ludwig Institute for Cancer Research...
- Celldex Therapeutics and Ludwig Institute for Cancer Research Announce Cancer...
- Press release article from: PR Newswire October 23, 2006 700+ words
...the international Ludwig Institute for Cancer Research...these antigens (NY-ESO-1, MAGE3, and...Technology Licensing at the Ludwig Institute. "This system has...agreement with the Ludwig Institute, an acknowledged...
- Celldex Ludwig Institute announce cancer antigen license.
- Newspaper article from: BIOTECH Patent News October 1, 2006 700+ words
...the international Ludwig Institute for Cancer Research...these antigens (NY-ESO-1, MAGE3, and...Technology Licensing at the Ludwig Institute. "This system has...agreement with the Ludwig Institute, an acknowledged...
- Data on cancer vaccines described by investigators at University of Lausanne,...
- Newspaper article from: Cancer Vaccine Week August 18, 2008 700+ words
...cell responses against NY-ESO-1. The induced CD4+ T cells...directed against a single NY-ESO-1 epitope spanning amino acids...colleagues, University of Lausanne, Ludwig Institute for Cancer Research. The researchers...our study shows that rLV/ESO induces potent and comprehensive...
